CD4 and neoplasm: For an anti‐cancer immune response to generate efficiently, dendritic cells (DCs) are required to migrate from the tumor site to secondary lymphoid organs (SLOs) and present major histocompatibility complex (MHC) molecule–peptide antigen complexes to CD4+ and CD8+ T cells.58, 59, 60, 61